BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/17/2023 8:50:53 AM | Browse: 33 | Download: 2
Publication Name |
World Journal of Gastroenterology |
Manuscript ID |
87228 |
Country/Territory |
China |
Category |
Medicine, Research & Experimental |
Manuscript Type |
Basic Study |
Article Title |
Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Zheng-Yan Yang, Yi-Wei Zhao, Jing-Rui Xue, Ran Guo, Zhi Zhao, Han-Di Liu, Zhi-Guang Ren and Ming Shi |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Youth Fund of National Natural Science Foundation of China |
81803575 |
Youth Fund of National Natural Science Foundation of China |
31902287 |
Kaifeng Science and Technology Development Plan Project |
2203008 |
College Students Innovation and Entrepreneurship Training Program of Henan University |
20231022007 |
Key Specialized Research and Promotion Project of Henan Province in 2023 |
232102311205 |
Henan Medical Science and Technology Research Program Project |
LHGJ20210801 |
|
Corresponding Author |
Zhi-Guang Ren, Doctor, Associate Professor, Department of Pathology, School of Basic Medical Science, Henan University, No. 1 Jinming Street, Kaifeng 475004, Henan Province, China. renzhiguang66@outlook.com |
Key Words |
Gastric cancer; Trastuzumab resistance; Thioridazine; S-phase kinase associated protein 2; Glycolysis |
Core Tip |
S-phase kinase-interacting protein 2 (Skp2) has been shown to be a reliable prognostic indicator of unfavorable outcomes for gastric cancer (GC). However, no agents specifically targeting Skp2 have been successfully developed. In this study, we proved that thioridazine restores the sensitivity of GC cells to trastuzumab both in vivo and in vitro by inhibiting Skp2-mediated glycolysis. Furthermore, the combination of thioridazine and lapatinib exhibits enhanced inhibitory effects compared with either monotherapy on the growth and survival of trastuzumab-resistant GC cells. Overall, this study suggests the potential of a thioridazine-based therapy to overcome trastuzumab resistance in human epidermal growth factor receptor 2-positive GC by targeting Skp2. |
Citation |
Yang ZY, Zhao YW, Xue JR, Guo R, Zhao Z, Liu HD, Ren ZG, Shi M. Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis. World J Gastroenterol 2023; In press |
 |
Received |
|
2023-09-17 15:07 |
 |
Peer-Review Started |
|
2023-09-17 15:08 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-10-08 05:08 |
 |
Revised |
|
2023-10-19 12:17 |
 |
Second Decision |
|
2023-11-14 01:12 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Company Editor-in-Chief |
|
2023-11-17 08:50 |
 |
Articles in Press |
|
2023-11-17 08:50 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2023-11-28 03:18 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Assistant Editor |
Assistant Editor |
Science Editor |
Xin-Liang Qu |
Reviewer Code |
03731081, and 03769068 |
Editorial Director |
|
Journal Chief Editor |
|
Company Chief Editor |
Jin-Lei Wang |
Language Editor |
|
Production Editor |
Si Zhao |
Responsible Production Editor |
Hua-Ge Yu |
Responsible Science Editor |
|
Proofing Editorial Director |
Jin-Lei Wang |
Proofing Editor-in-Chief |
Lian-Sheng Ma |
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345